Immunology of gene and cell therapy

CLS-logo.png The outcome of gene and cell therapies is determined in large part by the immune system. On one hand, immune responses can be drivers for therapy-induced immunotoxicities as well as loss of therapy in instances when components of the vector, its gene product or cells producing the therapeutic protein are recognized by the immune system and eliminated. On the other hand, gene and cell-based therapies can be designed to engage the immune system leading to either induction or suppression of immune responses in order to combat cancer or autoimmune disorders, respectively.    

At CLS, we have expert knowledge of the immune system and we are able to support gene and cell therapy customers wishing to assess the impact of their gene or cell therapy product on immune cells. We will work with viral constructs and cell products provided by you, using your preferred handling and transduction methods. 

Our services

Below are some of the services we offer in the field of gene and cell therapy: 

  • Assessment of transduction efficiency using different immune cells or tumor cells; measurement of transgene expression by flow cytometry or the Incucyte Live-Cell Analysis System
  • Measuring lytic potential of oncoviruses in tumor cell lines
  • Optimization and generation of chimeric antigen receptor (CAR)-transduced immune cells e.g. T cells, Tregs and macrophages
  • Design and performance of downstream experiments consistent with the immunomodulatory genes’ or cell products’ mode of action including cell proliferation, cytokine production, expression of activation markers, cytotoxicity towards tumor cells, phagocytosis